News for Interpace Biosciences Inc (PF42.MU)

In-network status for ThyGeNEXT® and ThyraMIR® with State’s Largest Payer PARSIPPANY, NJ, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences,...

PARSIPPANY, NJ, Feb. 24, 2021 -- Interpace Biosciences, Inc. , an emerging leader in enabling personalized medicine, today announced that on February 24, 2021, the Company satisfied the... | February 24, 2021

PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) ("Interpace Biosciences" or the "Company"), an emerging leader in

Today's Daily Dose brings you news about Nektar's collaboration with Merck; Pfizer initiating a refractory multiple myeloma study; Processa Pharma's strategic financing; and vTv Therapeutics' initiation of a phase 1 multiple ascending dose study of HPP737.

PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized me...

Shares of Interpace Biosciences Inc. (IDXG) are gaining nearly 15% on Thursday morning after the company announced a contract for thyroid testing with Blue Cross Blue Shield of Florida.